22 completed, 5 terminated, 4 active not recruiting, 3 recruiting. 17 Phase 2, 14 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 12, Active not recruiting 2, Terminated 2, Recruiting 1 |
| Phase 1 | 14 | Completed 9, Recruiting 3, Terminated 2 |
| Phase 3 | 6 | Completed 3, Active not recruiting 2, Terminated 1 |
Follow Vir Biotechnology, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 100 | 2025-08-05 | 2026-01-16 |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 150 | 2025-07-30 | 2026-07-13 |
| Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors VIR-5525, Pembrolizumab - Solid Tumor Malignancies, EGFR Positive Solid Tumors | Phase 1 | Recruiting | Vir Biotechnology, Inc. | 450 | 2025-07-22 | 2026-04-13 |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Tobevibart, Elebsiran - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 124 | 2025-03-12 | 2026-04-08 |
| Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) BRII-179, BRII-835 (VIR-2218), PEG-IFNα - For Treatment of Chronic Hepatitis B Virus Infection | Phase 2 | Completed | Brii Biosciences Limited | 150 | 2024-08-06 | 2026-10-21 |
| Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy VRON-0200-AdC6, VRON-0200-AdC7, VIR-2218 - Chronic Hepatitis B | Phase 1 | Completed | Virion Therapeutics | 35 | 2023-09-26 | 2026-08-19 |
| Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients PEG-IFNα, BRII-835 - Chronic Hepatitis B Virus Infection | Phase 2 | Completed | Brii Biosciences Limited | 86 | 2023-08-22 | 2026-10-20 |
| Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer VIR-5500, Androgen receptor signaling inhibitor (ARSI), Docetaxel - Hormone-refractory Prostate Cancer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 347 | 2023-08-10 | 2026-10-21 |
| A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 VIR-2218 - Renal Impairment | Phase 1 | Completed | Vir Biotechnology, Inc. | 28 | 2023-06-01 | 2026-10-16 |
| A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection VIR-3434, VIR-2218, TDF - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Vir Biotechnology, Inc. | 33 | 2023-05-10 | 2026-02-09 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo - Influenza A | Phase 2 | Terminated | Vir Biotechnology, Inc. | 2977 | 2022-10-30 | 2024-09-19 |
| Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 VIR-2218, VIR-3434 - Hepatic Impairment, Cirrhosis | Phase 1 | Completed | Vir Biotechnology, Inc. | 88 | 2022-09-21 | 2026-09-09 |
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. VIR-2218, VIR-3434, NRTI - Hepatitis D, Chronic | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 95 | 2022-09-17 | 2026-06-26 |
| To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers VIR-5818, pembrolizumab - Locally Advanced or Metastatic HER2-Expressing Cancers | Phase 1 / Phase 2 | Recruiting | Vir Biotechnology, Inc. | 645 | 2022-04-13 | 2026-08-19 |
| Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) sotrovimab - Covid19 | Phase 1 | Terminated | Vir Biotechnology, Inc. | 316 | 2022-03-28 | 2024-09-19 |
| Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study Questionnaire Administration, Sotrovimab, Biospecimen Collection - COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 20 | 2022-01-25 | 2025-02-13 |
| Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19 Sotrovimab - COVID-19 | Phase 2 | Terminated | GlaxoSmithKline | 8 | 2021-12-16 | 2024-01-03 |
| Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) Tenofovir Alafenamide, VIR-2218, Nivolumab - Chronic Hepatitis B | Phase 2 | Completed | Gilead Sciences | 103 | 2021-08-14 | 2025-07-24 |
| Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection VIR-2218, VIR-3434, PEG-IFNα - Hepatitis B, Chronic | Phase 2 | Completed | Vir Biotechnology, Inc. | 244 | 2021-07-11 | 2026-04-23 |
| A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants sotrovimab, Placebo to Biologic - Covid19 | Phase 1 | Completed | Vir Biotechnology, Inc. | 48 | 2021-07-06 | 2024-06-07 |
Showing 20 of 35. Sign in to see all of them.
COVID-19 (12) · Hepatitis (11) · Hepatitis B, Chronic (10) · Hepatitis B (8) · Coronavirus Infections (6) · Hepatitis D (4) · Hepatitis D, Chronic (4) · Severe Acute Respiratory Syndrome (3) · Coronaviridae Infections (2) · Digestive System Diseases (2) · Liver Diseases (2) · Nidovirales Infections (2) · RNA Virus Infections (2) · Virus Diseases (2) · Fibrosis (1)
sotrovimab (11) · bamlanivimab (2) · bulevirtide (2) · pembrolizumab (2) · remdesivir (2) · DNA-(Apurinic or Apyrimidinic Site) Lyase (1) · Docetaxel (1) · Nivolumab (1) · Specimen Handling (1) · bebtelovimab (1) · cilgavimab and tixagevimab drug combination (1) · ensovibep (1) · etesevimab (1) · lufotrelvir (1) · peginterferon alfa-2a (1)
United States (21) · United Kingdom (12) · Australia (9) · New Zealand (9) · South Korea (9) · Spain (8) · Hong Kong (7) · Romania (7) · France (6) · Germany (6) · Singapore (6) · Moldova (5) · Thailand (5) · Canada (4) · China (4)
Xiaofei Chen (2) · Alpana Waghmare (1) · Ernesto Ramirez, PhD (1) · James Neaton, Prof. (1) · Jens Lundgren, Prof. (1) · Luca Foschini, PhD (1) · Prof. James Neaton (1) · Prof. Jens Lundgren (1) · Sue Currie, PhD (1)
PMID 34473343, PMID 41586499, PMID 35713300, PMID 34928698, PMID 33356051, PMID 34374951, PMID 34706189, PMID 34741731, PMID 34953520, PMID 35285853, PMID 35298440, PMID 35817072, PMID 35939810, PMID 35977462, PMID 36703019, PMID 37290591, PMID 37520411, PMID 37577112, PMID 37702920, PMID 37948759, PMID 37955825, PMID 38074312, PMID 38291279, PMID 38376227, PMID 39036981, PMID 39389081, PMID 39881564, PMID 39922466, PMID 40043858, PMID 40262279, PMID 40882923, PMID 41203919, PMID 41211943, PMID 41284195, PMID 41324898, PMID 42214405
2023 (2), 2019 (1)